{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(2)"],"submitter":["Nygaard B"],"pubmed_abstract":["<h4>Objective</h4>Patients are increasingly using and requesting LT4/LT3 combination treatment for persistent hypothyroid symptoms, but the efficacy and side effects of long-term therapy remain largely unexplored. This study aimed to describe the patient group experiencing a long-lasting impact of LT4/LT3 and evaluate their quality of life (QoL) and hypothyroid symptoms.<h4>Method</h4>We performed a cross-sectional study of 66 hypothyroid patients who had previously initiated LT4/LT3 combination therapy. The patients were grouped by current treatment into patients still receiving LT4/LT3 treatment (T3 responders) and patients who had discontinued LT3 treatment due to lack of effect (T3 non-responders). ThyPRO was used to evaluate QoL, and a validated symptom score was used to assess hypoth"],"journal":["European thyroid journal"],"pagination":["e240275"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11906148"],"repository":["biostudies-literature"],"pubmed_title":["Long-term outcomes of LT4/LT3 combination treatment for persistent hypothyroid symptoms."],"pmcid":["PMC11906148"],"pubmed_authors":["la Cour JL","Jensen CZ","Medici BR","Jorsal M","Nygaard B","Steffensen R","Carle A"],"additional_accession":[]},"is_claimable":false,"name":"Long-term outcomes of LT4/LT3 combination treatment for persistent hypothyroid symptoms.","description":"<h4>Objective</h4>Patients are increasingly using and requesting LT4/LT3 combination treatment for persistent hypothyroid symptoms, but the efficacy and side effects of long-term therapy remain largely unexplored. This study aimed to describe the patient group experiencing a long-lasting impact of LT4/LT3 and evaluate their quality of life (QoL) and hypothyroid symptoms.<h4>Method</h4>We performed a cross-sectional study of 66 hypothyroid patients who had previously initiated LT4/LT3 combination therapy. The patients were grouped by current treatment into patients still receiving LT4/LT3 treatment (T3 responders) and patients who had discontinued LT3 treatment due to lack of effect (T3 non-responders). ThyPRO was used to evaluate QoL, and a validated symptom score was used to assess hypoth","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2025-04-04T14:48:08.421Z","creation":"2025-04-04T14:48:08.421Z"},"accession":"S-EPMC11906148","cross_references":{"pubmed":["39982807"],"doi":["10.1530/ETJ-24-0275"]}}